Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 CMC Expands Bio-CMO Footprint with Icos Purchase | Contract Pharma
Breaking News

CMC Expands Bio-CMO Footprint with Icos Purchase

CMC Biopharmaceuticals A/S has reached an agreement with Lilly to buy the biologics development and manufacturing operation of ICOS Corp., which Lilly bought on in January 2007. CMC, a Copenhagen, Denmark-based bio-CMO, will purchase the biologics facility in Bothell, WA. The new operation, CMC ICOS Biologics Inc., will develop and manufacture therapeutic proteins for early clinical trials.

In a statement, the company said that it is planning “significant investment in the facility to enable production of late-stage clinical trial and commercial biopharmaceuticals.” CMC plans to retain the 127 employees currently working at the Bothell facility.
 
“We’re extremely excited about our acquisition of ICOS Biologics. We feel strongly that the skills inherent in the employees that work here are of great value to the biologics industry and will complement the abilities of our expert workforce in Europe,” said David Kauffmann, CMC’s chairman.

Mads Laustsen, CMC’s chief executive officer, remarked, “Our plans to upgrade the facility in order to manufacture commercial product will mean that we can provide additional services to both existing and new clients. Moreover, by establishing a presence in the USA, we’ve placed CMC in an enhanced position to actively seek opportunities to grow our business.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters